title: Using clinical trial data to tailor adjuvant treatments for individual patients.
abstract: The 2005 St. Gallen Consensus Panel provided recommendations for the treatment of early breast cancer which rely on target identification first. The foremost advance since 2005-demonstration of trastuzumab efficacy for patients with HER2-positive disease-was realized because an effective treatment was being evaluated and because the trial patients had the targeted disease as determined by quality-controlled assessment prior to study entry. The BIG 1-98 trial provides a striking reminder of patients' benefit from reliable pathological tumor assessment so that targeted therapies are effectively utilized. Several statistical methods facilitate use of clinical trial data for individualizing treatment. Subgroup analyses summarized using forest plots are essential for better understanding the disease and its treatment. The HERA trial illustrates the interpretation of relative and absolute treatment effects and estimating hazard rates over time as means to distinguish relevant differences across subgroups. Overview analyses, joint analyses, the STEPP (subpopulation treatment effect pattern plot) method and recursive partitioning are valuable tools.
authors: IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. mregan@jimmy.harvard.edu
authors: Meredith M
authors: MM
authors: Regan
authors: Richard D
authors: RD
authors: Gelber
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects; D011960:Receptors, Estrogen / Q000187:drug effects; D011980:Receptors, Progesterone; D016019:Survival Analysis; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000068878:Trastuzumab
references: Ann Oncol. 2005 Oct;16(10):1569-83
references: 16148022
references: J Clin Oncol. 1985 Oct;3(10):1418-31
references: 4045529
references: N Engl J Med. 2006 Apr 20;354(16):1667-9
references: 16625007
references: Breast Cancer Res. 2005;7(6):252-4
references: 16280051
references: Lancet. 2005 May 14-20;365(9472):1687-717
references: 15894097
references: Biostatistics. 2004 Jul;5(3):465-81
references: 15208206
references: Ann Oncol. 2006 Dec;17(12):1772-6
references: 17071934
references: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references: 11553815
references: N Engl J Med. 2005 Oct 20;353(16):1659-72
references: 16236737
references: J Clin Oncol. 2007 Sep 1;25(25):3846-52
references: 17679725
references: Stat Med. 2000 Oct 15;19(19):2595-609
references: 10986536
references: J Clin Oncol. 2007 Feb 10;25(5):486-92
references: 17200148
references: N Engl J Med. 2005 Oct 20;353(16):1673-84
references: 16236738
references: J Clin Oncol. 1996 Oct;14(10):2738-46
references: 8874335
references: Lancet. 2005 Apr 9-15;365(9467):1308
references: 15823379
references: Breast. 2005 Dec;14(6):582-93
references: 16199162
references: Lancet. 2007 Jan 6;369(9555):29-36
references: 17208639
references: N Engl J Med. 2005 Dec 29;353(26):2747-57
references: 16382061
references: JAMA. 2006 Apr 12;295(14):1658-67
references: 16609087